Monday, October 16, 2017 4:51:01 PM
2. The device is being tested as reported in Form 7 of October 2017.
3. The company continues to remain focused on it's path to commercialization/monetization.
4. The board heavily deliberated in regards to targeting one specific disease for testing. Meaning, one clear path to commercialization/monetization. Versus multiple paths for multiple diseases at one time. A clear path has been established.
5. It's the Boards job to figure out what they/we are doing. It's been figured out. Expect news by the end of the month.
6. ????
7. Guy LaTorre stepped down to pursue other interests as reported in the News Release. Nothing more to add. To Guy's credit, he is responsible for the non-monetary strategic partnership with Zeptometrix that remains ongoing and does not conflict with a focused strategy moving forward.
8. The fundamental mission of the company has not changed. The strategy is more streamlined/focused as explained above.
Good Afternoon JB
2. Regarding Guy LaTorre - See #7 above.
Good Afternoon JB
Thank U & Ur Welcome 2 JB
/////AMG
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM